AbbVie Inc. $ABBV Shares Sold by Romano Brothers AND Company

Romano Brothers AND Company trimmed its position in shares of AbbVie Inc. (NYSE:ABBV) by 1.8% during the second quarter, Holdings Channel.com reports. The institutional investor owned 123,458 shares of the company’s stock after selling 2,268 shares during the period. AbbVie accounts for 3.1% of Romano Brothers AND Company’s investment portfolio, making the stock its 3rd largest holding. Romano Brothers AND Company’s holdings in AbbVie were worth $31,067,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. MFA Wealth Services lifted its stake in AbbVie by 11.8% in the second quarter. MFA Wealth Services now owns 3,401 shares of the company’s stock valued at $856,000 after acquiring an additional 358 shares during the last quarter. Raleigh Capital Management Inc. increased its stake in shares of AbbVie by 17.8% during the 2nd quarter. Raleigh Capital Management Inc. now owns 18,091 shares of the company’s stock worth $4,552,000 after purchasing an additional 2,730 shares during the last quarter. Landaas & Co. WI ADV raised its holdings in shares of AbbVie by 1.1% in the 2nd quarter. Landaas & Co. WI ADV now owns 5,954 shares of the company’s stock valued at $1,498,000 after purchasing an additional 66 shares during the period. River Street Advisors LLC lifted its stake in AbbVie by 1.5% in the 2nd quarter. River Street Advisors LLC now owns 13,777 shares of the company’s stock valued at $3,467,000 after purchasing an additional 205 shares during the last quarter. Finally, Laurel Oak Wealth Management LLC lifted its stake in AbbVie by 6.1% in the 2nd quarter. Laurel Oak Wealth Management LLC now owns 3,889 shares of the company’s stock valued at $979,000 after purchasing an additional 224 shares during the last quarter. 70.23% of the stock is owned by institutional investors.

AbbVie Stock Down 0.6%

Shares of ABBV stock opened at $249.20 on Friday. AbbVie Inc. has a 12-month low of $190.75 and a 12-month high of $267.47. The company has a market capitalization of $440.29 billion, a PE ratio of 70.40, a price-to-earnings-growth ratio of 0.83 and a beta of 0.30. The firm has a 50 day moving average price of $244.94 and a two-hundred day moving average price of $226.12.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating the consensus estimate of $3.61 by $0.04. The company had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The firm’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, research analysts expect that AbbVie Inc. will post 14.07 EPS for the current year.

AbbVie Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend was Wednesday, July 15th. AbbVie’s dividend payout ratio is currently 195.48%.

Analysts Set New Price Targets

ABBV has been the topic of a number of recent analyst reports. UBS Group boosted their price target on AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a research report on Monday, July 13th. Barclays raised their price objective on AbbVie from $275.00 to $300.00 and gave the company an “overweight” rating in a research report on Wednesday, July 29th. Sanford C. Bernstein restated a “market perform” rating on shares of AbbVie in a research note on Tuesday, June 23rd. DZ Bank raised AbbVie from a “hold” rating to a “strong-buy” rating in a report on Thursday, April 30th. Finally, Bank of America lifted their price objective on shares of AbbVie from $234.00 to $276.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, AbbVie currently has a consensus rating of “Moderate Buy” and an average price target of $275.50.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Neuroscience growth is gaining momentum: AbbVie’s neuroscience franchise delivered strong first-half growth, with Parkinson’s treatment Vyalev accelerating. Potential approval and commercialization of tavapadon could provide another growth driver in the second half of 2026. Can ABBV’s Neuroscience Drugs Drive Growth in the Second Half of 2026?
• Positive Sentiment: Post-Humira diversification remains a key bullish theme: Analysts and investors point to resilient revenue growth from AbbVie’s next-generation immunology and aesthetics portfolio. Wolfe Research upgraded AbbVie on pipeline strength and valuation, while BNP Paribas Exane also expects the stock to rise. Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation
• Positive Sentiment: Recent operating performance supports the growth case: AbbVie’s reported first-quarter 2026 revenue increased 12.4% year over year, while adjusted EPS exceeded internal expectations despite an acquired research-and-development charge. Could AbbVie Inc. Post-Humira Transformation Drive the Next Phase of Growth?
• Neutral Sentiment: Pipeline updates add potential but remain clinical-stage catalysts: AbbVie is expanding Alzheimer’s research with ABBV-1758 and studying Rinvoq against Humira in rheumatoid arthritis, while real-world China data for upadacitinib in atopic dermatitis could help reinforce Rinvoq’s commercial position. AbbVie Steps Deeper Into Alzheimer’s
• Negative Sentiment: Risks include valuation and pipeline uncertainty: A comparison with Bristol-Myers Squibb highlighted that AbbVie trades at a considerably richer valuation. Separately, the partners clarified a setback in the Phase 3 epcoritamab lymphoma study, and Erste Group Bank lowered its AbbVie earnings estimates—both potential sources of caution. Could AbbVie Win as Genmab Faces a New Regulatory Test for Epcoritamab?

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.